We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Poor Showing Before FDA Advisory Panel Prompts Amarin to Slash Staff
Poor Showing Before FDA Advisory Panel Prompts Amarin to Slash Staff
October 25, 2013
Amarin has reduced its workforce by almost half in a bid to stay solvent while it wages an “uphill battle” to obtain a new indication for its flagship heart drug Vascepa.